China approves new anticancer drug for clinical tests

  • ASEAN+
  • Thursday, 26 Mar 2020

XIAMEN (Xinhua): A new anticancer drug capable of "lysing" cancer cells has been granted approval to enter clinical trials in China, the drug's developers said Wednesday (March 25).

The drug, jointly developed by Xiamen University and two Chinese companies, is the latest attempt to use oncolytic virotherapy to treat a number of solid cancers, including head-neck carcinoma, lung cancer, colorectal cancer and liver cancer.

Oncolytic virotherapy is an immunotherapy that "lyses," or destroys, cancer cells and releases tumour-associated antigens that will stimulate the patient's immune response.

Researchers with Xiamen University said they constructed a new-generation oncolytic virus, encoding PD-1 antibodies, that boasts a higher cure rate on tumour-bearing mice.

The virus can directly deliver PD-1 antibodies within the tumours, leading to "immunogenic death" of tumour cells, a process that will lure in activated T-cells to kill more cancer cells, researchers said.

Further studies show the virus eliminates the local tumour and distant tumour by stimulating the antitumour immune response, and the cured mice were found to have a long-term antitumour immune memory and can resist the re-attack of the same tumour cells. - Xinhua

Article type: free
User access status:

cancer , new , drug , china , trials


Did you find this article insightful?


100% readers found this article insightful

Across The Star Online